For most of my life, marijuana has been considered a taboo topic that wasn't discussed openly and was swept under the rug by federal, state, and local officials. It was understood that a black market existed, but the "war on drugs" was always in force, with marijuana placed side by side with heroin and cocaine as scourges of society.
But as we near 4/20, a date of significance within the cannabis community that's celebrated by smoking or consuming marijuana, what's crystal clear is that this is no longer a taboo topic or an illicit industry. In a relatively short amount of time, the pot industry and the cannabis movement have come an incredibly long way. Here are 16 facts that unequivocally show that cannabis is now a mainstream topic and is here to stay.
Image source: Getty Images.
Believe it or not, more than 40 countries around the world have legalized medical marijuana in some capacity. You might know about most European countries doing so, but it might be surprising to learn that Thailand, a country known for some of the harshest penalties in the world on drug users, gave the green light to medical weed a few months ago. South Korea, another very strict country with regard to handling drug offenses, became the first East Asian country to legalize medical pot in November.
In addition, two countries -- Uruguay and Canada -- have legalized recreational marijuana. Canada's passage of the Cannabis Act last year allowed it to become the first industrialized country in the world to allow people to legally consume pot. By 2022, Wall Street analysts forecast that Canada could be generating as much as $6 billion in full-year sales.
Although marijuana remains an illicit substance at the federal level, it hasn't stopped 33 states from legalizing the drug for medical purposes. Even traditionally conservative states such as Utah have recently OK'd medical marijuana for select ailments. There are also 10 states that allow for adult-use consumption.
Image source: Getty Images.
To build on the previous point, we're also seeing pot legalization occur entirely at the legislative level. Not every state has the initiative and referendum process whereby signatures are gathered to get a measure on a ballot for the public to vote on. In certain states such as Vermont, the state's legislature has been responsible for legalizing cannabis.
People like weed! It was once a drug that only 25% of the population wanted to see legalized in Gallup's 1995 national poll, but the October 2018 survey showed that an all-time record 66% of respondents now favor legalizing marijuana in the United States. In all major surveys other than Gallup, the results are relatively consistent, with a majority of respondents favoring legalization.
Historically, Republicans and senior citizens have had notably more negative views of cannabis than other political parties and younger Americans. But in the October Gallup survey, we saw seniors and Republicans demonstrate favorability toward legalization for the first time in history. Their support might be the secret ingredient needed to actually amend federal cannabis laws in the United States.
Image source: GW Pharmaceuticals.
Federal and state governments aren't the only one's getting in on the action. The U.S. Food and Drug Administration (FDA) also legalized its very first cannabis-derived drug in June 2018 from GW Pharmaceuticals (NASDAQ: GWPH). GW Pharmaceuticals' Epidiolex, a cannabidiol (CBD)-based medicine, reduced seizure frequency from baseline by roughly 30% to 40% in two rare types of childhood-onset epilepsy. GW Pharmaceuticals launched this trendsetting therapy in early November at a list price of $32,500 a year, and it's currently the only FDA-approved treatment for Dravet syndrome.
We also saw the U.S. government finally differentiate between hemp plants and cannabis plants, at least on paper. The passage of the Farm Bill in December 2018 legalized hemp production and processing, and it firmly differentiated between hemp and cannabis on the controlled-substances list. The Farm Bill becoming law is particularly important since hemp plants tend to be rich in CBD, the non-psychoactive cannabinoid best known for its perceived medical benefits.
Marijuana stocks have long been listed on the over-the-counter (OTC) exchange, but some of the most influential ones have moved to the New York Stock Exchange or Nasdaq. This includes the largest pot stock in the world by market cap, Canopy Growth (NYSE: CGC), as well as Aurora Cannabis (NYSE: ACB), the projected leader in peak annual pot production in Canada. Both Canopy and Aurora moved to the NYSE from the OTC exchange in 2018, and they're now listed side by side with time-tested businesses that have, in some cases, been around for more than a century.
Image source: Getty Images.
On top of just uplistng from the OTC exchange, which seven pot stocks have done since February 2018, a small handful of weed stocks have gone the initial public offering (IPO) route on reputable U.S. exchanges. None has had more success than Tilray (NASDAQ: TLRY), which raised gross proceeds of $153 million by listing 9 million shares at $17 in July when it IPO'd on the Nasdaq. Two months later, Tilray saw its stock run (briefly) to $300 before coming back to Earth.
To our north, the legalization of recreational marijuana has allowed banks the ability to offer basic banking services to marijuana stocks, which have long been reliant on dilutive bought-deal offerings that include common stock sales, convertible debentures, stock options, and/or warrant offerings. Traditional loans and lines of credit provide a non-dilutive means for pot stocks to access capital. In other words, shareholders rejoice!
Just how much marijuana could Canada produce? The top 11 producers, which include Aurora Cannabis's 780,000 kilos at its annual peak, Canopy Growth's up to 550,000 kilos, and Tilray's more than 100,000 kilos, should come very close to 3 million kilos by themselves. If you tack on a number of mid-tier, smaller, and non-public growers, then 4 million kilos a year, in aggregate, becomes very plausible by perhaps 2022 or 2023.
Image source: Getty Images.